Mice lacking caspase-2 are protected from behavioral changes, but not pathology, in the YAC128 model of Huntington

Jeffrey B Carroll1, Amber L Southwell, Rona K Graham

  • 1Centre for Molecular Medicine and Therapeutics, Child and Family Research Institute, Department of Medical Genetics, University of British Columbia, Vancouver, V5Z 4H4, Canada. mrh@cmmt.ubc.ca.

Abstract

Insights

Mice lacking caspase-2 (casp2) showed improved motor and cognitive functions in a Huntington Disease (HD) model. However, core pathological hallmarks of HD remained unchanged, suggesting casp2 inhibition may offer symptomatic relief.

Area of Science:

  • Neuroscience
  • Genetics
  • Biochemistry

Background:

  • Huntington's Disease (HD) involves caspase activation and protein cleavage.
  • Caspase-2 (casp2) activity is implicated in HD pathogenesis, but its specific substrates are unknown.
  • A substrate-agnostic approach was used to investigate casp2's role in HD progression.

Purpose of the Study:

  • To investigate the role of caspase-2 (casp2) in the progression of Huntington's Disease (HD).
  • To determine if the absence of casp2 affects the behavioral and pathological features of HD in a mouse model.

Main Methods:

  • Utilized YAC128 mouse model for Huntington's Disease (HD).
  • Generated YAC128 mice completely lacking caspase-2 (casp2-/-).
  • Assessed motor and cognitive functions using various behavioral tasks and high-resolution MRI for neuropathology.

Main Results:

  • Mice lacking casp2 demonstrated protection from motor and cognitive deficits in the HD model.
  • Specific pathological features of HD, including striatal volume loss and testicular degeneration, were not altered by the absence of casp2.
  • High-resolution MRI confirmed neuropathology in YAC128 mice was unaffected by casp2 ablation.

Conclusions:

  • Behavioral improvements in the absence of pathological changes suggest distinct pathways for HD-related dysfunction and cell death.
  • Inhibition of caspase-2 (casp2) activity may be linked to symptomatic improvement in Huntington's Disease (HD).